Search results
Jie Du is a Professor in the School of Mathematics and Statistics. RESEARCH INTERESTS. Prof Du is a member of the School's Algebra and Number Theory and Combinatorics research groups. His interests lie in the representation theories on algebraic and quantum groups, finite groups of Lie type, finite dimensional algebras, and related topics.
- Professor Jie Du | UNSW Research
Jie Du is a Professor in the School of Mathematics and...
- Select Publications by Professor Jie Du | UNSW Research
Du J; Shu B, 2009, 'Representations of finite Lie algebras',...
- JIE DU's INFORMATION PAGE - UNSW Sites
JIE DU's INFORMATION PAGE. Contact Information, Brief...
- Professor Jie Du | UNSW Research
Jie Du is a Professor of Pure Mathematics at UNSW, specializing in algebra and group theory. His research interests include quantum groups, finite groups of Lie type, and related topics.
- How Exactly Did You Start Building JDP Therapeutics?
- How Did You Make That Decision?
- So, People Really Didn’T Believe You Did Everything Yourself?
- Is That Why You Didn’T Rely on Outside Investors?
- Was There Anything You Were Unable to Do Yourself?
- What Was The Best Decision That You Made During This time?
- Why Did You Sell JDP When You did?
- What Are You Currently Doing?
- Did Being A Woman Add Any Challenges to Launching Jdp?
- What Advice Would You Give An Entrepreneur Who’s Having Trouble Raising Funds?
- GeneratedCaptionsTabForHeroSec
To be honest, it’s all about developing a product. Since I was already a scientist and drug developer, I knew how to develop a drug, but I didn’t know what drug to develop. I also knew I needed help on the business side, so I started going to business conferences in Philadelphia where I would network to meet professionals who could help me and prov...
Chris asked me to do market research, so I talked with several physicians who made me realize that the three potential drugs I’d come up with didn’t really have good market needs. One of the physicians mentioned that the injectable acute allergic reaction space had no new drugs. There was only a drug called diphenhydramine, also known as Benadryl, ...
No one took me seriously. I had such a big problem with investors because when they asked me—“Who came up with the clinical protocol? Who’s the inventor of the technology?”—and every answer was “I did it,” they didn’t believe me. My story is much different from the majority of other startups because they usually have a business person/founder who h...
I actually approached around 150 investors and pharmaceutical companies to beg for funding or to out-license my product, but it was so unproductive. After being turned down again and again, I went to friends and family for investment. The good thing with friends and family is they don’t know the pharmaceutical industry, but they know me. So, they g...
The lab work. I couldn’t do that on my own so I had to contract with laboratories and manufacturing facilities. But when you contract with CROs, there’re always two parts. One is the actual work and one is the design work. The fees were cut in half because I did the designing piece myself.
I would say my best decision was at the beginning when I found a business person to help me. I think that’s one of the most important factors in JDP’s success. Another good decision was actually to turn down a VC’s term sheet that we received, whose terms were very unfair to my earlier investors. That was the most difficult decision I had to make, ...
Once a drug is approved, you have to commercialize the drug. And for that we need a pharmaceutical sales team; JDP did not have that capability.
I’m working for the acquiring company and we have signed on for another year to continue working together. I’m also focusing on philanthropy work. My earnings from the sale of JDP were significantly bigger than a typical founder’s because there was no VC involvement, so I want to give back to society. I recently donated $5 million to University of ...
Yes. But for me, it’s not just being female, it’s being female and Chinese together that really made my life very difficult in fundraising. I did not have much success raising money from local investment groups or VCs in the U.S.—I had to go to China to raise money. I don’t think this is an issue anymore because the VCs who rejected me in the past ...
First of all, you have to keep trying more investors. But, sometimes if you’re just not able to convince other people how good you are, you have to just go ahead and do it yourself—not just say it, do it. Once you complete the Phase II and III clinical trials or receive FDA approval, there’s nothing they can doubt. If you’re a scientist like me, yo...
Learn how Dr. Jie Du launched and sold her pharmaceutical startup without VC funding, developing an injectable drug for acute allergic reactions. Read her interview with Ashton Tweed, a leading executive search firm in the life sciences industry.
The Jie Du Center for Innovation and Excellence for Drug Development promotes innovation in drug development through education, training and mentorship, while fostering collaboration between Pacific students and industrial scientists.
Du J; Shu B, 2009, 'Representations of finite Lie algebras', Journal of Algebra, 321, pp. 3197 - 3225. Deng B; Du J, 2007, 'Folding derived categories with Frobenius functors', Journal of Pure and Applied Algebra, 208, pp. 1023 - 1050.
JIE DU's INFORMATION PAGE. Contact Information, Brief History, Research interests, Publications, Preprints, Books, People
Read articles by Jie Du on ScienceDirect, the world's leading source for scientific, technical, and medical research.
